Market capitalization | $1.22b |
Enterprise Value | $1.46b |
P/E (TTM) P/E ratio | 11.82 |
EV/FCF (TTM) EV/FCF | 9.24 |
EV/Sales (TTM) EV/Sales | 4.23 |
P/S ratio (TTM) P/S ratio | 3.55 |
P/B ratio (TTM) P/B ratio | 1.84 |
Revenue growth (TTM) Revenue growth | 13.16% |
Revenue (TTM) Revenue | $344.30m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
2 Analysts have issued a Innoviva forecast:
2 Analysts have issued a Innoviva forecast:
Dec '23 | |
Current assets | 344 344 |
Fixed assets | 899 899 |
Total Assets | 1,244 1,244 |
Dec '23 | |
Equity | 675 675 |
Debt capital | 569 569 |
Total Capital | 1,244 1,244 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
Head office | United States |
CEO | Pavel Raifeld |
Employees | 112 |
Founded | 1996 |
Website | www.inva.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.